Pharmaceuticals, Biotechnology & Life Sciences

Belite Bio insider sales by CSO Nathan Mata are a routine liquidity move amid strong regulatory progress and bullish AMD prospects.

Insider buying of ProMIS Neurosciences signals confidence in its Phase II clinical progress, precision‑medicine platform, and value‑based reimbursement potential – a bullish cue for investors.

Axsome’s insider purchases signal confidence in Auvelity’s FDA fate and pipeline growth, showing how executive PSUs align with commercial milestones and investor upside.

Perceptive Advisors’ latest 555k‑share purchase of MeiraGTx (10.8m total, 1.16% stake) signals confidence in its gene‑therapy platform; watch regulatory milestones and warrant upside for future growth.

CEO insider buying at CryoPort signals confidence in its growing regenerative‑medicine logistics market, with disciplined accumulation boosting long‑term growth prospects.

Insider buying frenzy at Prelude Therapeutics: 2.8 M shares, $4.44 each, signals confidence amid IPO‑style offering, potential upside, and dilution risks.

CEO Daniel Faga sold 11,000 AnaptysBio options—routine equity cash‑management, no impact on the biotech’s strong pipeline or shareholder value.

Insightful look at Martine Rothblatt’s 10(b)(5)(1) trades at United Therapeutics and what it signals for investors in the pulmonary hypertension market.

Day One Biopharmaceuticals merges with Servier, closing for $2.5 billion. The deal delists Day One, gives Servier an oncology pipeline, and ends public exposure for shareholders.

Belite Bio’s CEO vests RSUs amid tinlarebant’s FDA breakthrough status, signaling strong clinical progress and insider confidence in future growth.